Cytokinetics
Trade Cytokinetics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
As of today, Cytokinetics(CYTK) shares are valued at $62.05. The company's market cap stands at 7.64B, with a P/E ratio of -9.51.
On 2026-03-18, Cytokinetics(CYTK) stock moved within a range of $60.82 to $63.02. With shares now at $62.05, the stock is trading +2.0% above its intraday low and -1.5% below the session's peak.
Trading volume for Cytokinetics(CYTK) stock has reached 1.39M, versus its average volume of 2.17M.
The stock's 52-week range extends from a low of $29.31 to a high of $70.98.
The stock's 52-week range extends from a low of $29.31 to a high of $70.98.
CYTK News
Cytokinetics recently announced that four presentations on MYQORZO™ (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy were delivered at the Am...
New insider activity at Cytokinetics ( (CYTK) ) has taken place on March 16, 2026. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful inve...
Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. T...